Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin Combination Chemotherapy
Conditions
Interventions
Olanzapine Tablets
Placebo
Locations
1
China
Sun Yat-sen University
Guangzhou, Guangdong, China
Start Date
January 18, 2022
Primary Completion Date
December 31, 2023
Completion Date
March 31, 2024
Last Updated
February 6, 2023
NCT07403370
NCT04833023
NCT06314906
NCT04472143
NCT01857232
NCT01111851
Lead Sponsor
Shi Yanxia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions